Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Biosimilar User Fee Talks Begin With Industry Negotiating Amongst Itself

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA asks negotiators from the four industry groups to coordinate proposed changes as BsUFA renewal talks get underway.


Related Content

Biosimilar User Fee Agreement Offers FDA Funding Boost, Fee Structure Overhaul
Two Out Of Three Ain't Bad: Biosimilar User Fee Talks Completed
FDA Proposes Dedicated Biosimilar 'Unit' For BsUFA II
FDA Met Biosimilar Review Timelines But Missed Meeting Goals In 2015
Biosimilars Reviews Could Be Extended Two Months In BsUFA II
Biosimilars Forum: How Do You Create A Brand-Generic Coalition? Don’t Talk About Naming
Biosimilar User Fee Negotiations Under Way; Timetable Compressed


Related Companies